Kipferon suppositories vagin.-Recto. 5 pieces

$10.30

Kipferon suppositories vagin.-Recto. 5 pieces

Quantity:

Description

Composition
Active substance:
– immunoglobulin complex preparation (TRC) – 0.2 g – interferon alpha-2b human, recombinant – 500 000 IU
Excipients:
– fat special purpose “SolPro” for sweet chocolate and candies – 0.838 g – solid paraffin oil P-2 – 0.085 g – emulsifier “Hard” (T-2) – 0.085 g – disodium hydrogenphosphate dodecahydrate – 0,055mg – sodium dihydrogen phosphate dihydrate – 0,018mg – sodium chloride – 0,110mg – purified water – 0.012 g of
Description:
Suppositories white, white to yellowish white or light-beige color with a characteristic smell, a cylindrical shape with a pointed end, in a longitudinal section homogeneous. On the cut tolerance of air core or funnel-shaped depressions. Heterogeneity of coloring in the form of marbling.
Product form:
5 suppositories in blisters. 1 contour cellular packaging together with instructions for use in a pile of cardboard.
Contraindications
Hypersensitivity of the individual components, I trimester pregnancy, lactation.
Indications
The drug is used in the treatment of diseases associated with secondary immunodeficiency – acute respiratory diseases, inflammatory diseases of the oropharynx bacterial and viral etiology in children and adults; – acute viral (rotavirus) and bacterial (salmonellosis, dysentery, colibacillosis), intestinal infections, including manifestations of intestinal dysbiosis of various severity in children; – urogenital chlamydia in women (including pregnant women in II-III trimesters of pregnancy), including manifestations of vaginal dysbiosis, vulvovaginitis, cervicitis of the uterus, cervical erosion.
Interaction with other drugs
Negative impact on other drugs were observed.
Overdose
Cases of overdose are not known.
pharmachologic effect
Pharmacological group:
MIP – cytokine.
ATC code: L03AH
Pharmacological properties:
Suppositories “Kipferon” is a complex formulation comprising human recombinant interferon-alpha2 and complex immunoglobulin preparation (TRC). Interferon-alpha 2 is an activator of the innate and adaptive immune system possesses pronounced antiviral activity, increases protection from viral, chlamydial, mycoplasmal and bacterial infections, exerts immunomodulatory effect in the development of immunological reactions, and contributes to the preservation of normal flora of intestine and vagina. The biological activity of the alpha 2 interferon is realized through interaction with a receptor apparatus of immune and other cells, leading to increased expression of HLA I and HLA II molecules on the surfaces of all cell types and the regulation of cell cooperation, increase the activity of natural killer cells, as well as its intact cells the stability against their cytolytic action proliferation CD8 T cells. It increases the production of gamma interferon natural killer cells. An integrated instrumentation immunoglobulin preparation comprises specific and nonspecific immunoglobulins of classes G, M, A. The combination of antiviral, Chlamydia, antibacterial and antitoxic antibodies belonging to different classes of immunoglobulins provides agglutination, neutralization and precipitation etiotropic pathogenic agents. The area of ​​application ensures stabilization of interferon secrets mucosal normalizes local immunity due Incoming IgA and IgM with suppositories (substitutive effect) increases the activity of cytokines locally formed.
Pharmacodynamics:
– immunomodulatory;
– antiviral;
– Chlamydia.
Conditions of supply of pharmacies
Sold without a doctor’s prescription.
side effects
Not registered.
special instructions
When used in the recommended doses, the drug has no effect on the behavior or functional performance of the organism, and also does not affect the ability to drive, mechanisms.
Storage conditions
Store at a temperature of from 2 ° C to 8 ° C, the reach of children.
Dosing and Administration
“Kipferon” applied rectally and vaginally. The drug is used in combination with conventional means pathogenetic treatment of infectious diseases, as well as indications of antibiotics. The method and dosage regimen, as well as use in the combined treatment determined by the doctor depending on the diagnosis, severity and disease severity. Acute respiratory diseases, inflammatory diseases of the oropharynx bacterial and viral etiology: the suppositories are administered rectally (mainly after the act of defecation), children up to 1 year for one suppository a day for children up to 12 years – 1 suppository twice a day in adults and children over 12 years – 1 suppository three times a day. The most efficient and appropriate assignment “Kipferona®” in the acute period (preferably within 3 days). Duration of treatment is determined etiology form of disease severity, presence of concomitant complications, and pathological conditions in 5-7 days.
Acute viral (rotavirus) and bacterial (salmonellosis, dysentery, colibacillosis), intestinal infections, including manifestations of intestinal dysbiosis of various severity in children: the suppositories are administered rectally (mainly after the act of defecation), children up to 1 year for one suppository per day, children up to 12 years – 1 suppository twice a day in adults and children over 12 years – 1 suppository three times a day. The most effective and efficient use of the drug in the acute period (preferably within 3 days). Duration of treatment is determined etiology form of disease severity, presence of concomitant complications, and pathological conditions in 5-7 days.
Urogenital chlamydia in women (including pregnant women in II-III trimesters of pregnancy), including manifestations of vaginal dysbiosis, vulvovaginitis, cervicitis of the uterus, cervical erosion: suppositories injected deep intravaginal (before contact with the posterior vaginal vault and cervix) 1-2 suppository, depending on the severity of the disease, twice a day. The course of treatment is an average of 10 days; in the presence of cervical erosion, use of the drug is continued until it epithelialization. According to the testimony of the course of treatment can be repeated after one month. Treatment should begin during the first days after menstruation. Before the introduction is recommended to remove the mucus from the vaginal mucous membranes and cervix.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

Binnofarm

There are no reviews yet.

Add your review